000			03189nam a2200349 c 4500
001			77904
003			ES-MaUEC
005			20230202102350.0
008			141113s2014 au | s |||| 0|eng d
020			_a9783709118184
040			_aES-MaUEC
050		4	_aQR189 _b.L853 2014 EB
082	0	4	_a615.372
245	0	0	_aNovel Technologies for Vaccine Development _cedited by Igor S Lukashevich, Haval Shirwan
260			_aVienna _bSpringer _c2014
300			_a1 recurso en línea (XIV, 386 p.) _b35 il.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aReverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
520			_aThis book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must readâ€{u09AF}r all those involved in vaccine development, both in academia and industrial vaccine development.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER
650		7	_aVacunas _0comprobar BNE19900984775 _2embne _9140409
700	1		_aLukashevich, Igor S. _eeditor literario _986899 _0Local
700	1		_aShirwan, Haval _eeditor literario _986900 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-7091-1818-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783709118184
907			_a.b12843830 _b10-10-17 _c23-02-15
998			_am _a_alco _a_vill _b05-07-17 _cm _dz _ef _feng _gau _h0
945			_aQR189 .L853 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11556742 _z06-04-17
999			_c77904 _d77904 _x1